Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Retatrutide by Eli Lilly and Co for Obesity: Likelihood of Approval
Retatrutide is under clinical development by Eli Lilly and Co and currently in Phase III for Obesity. According to GlobalData,...
Retatrutide by Eli Lilly and Co for Type 2 Diabetes: Likelihood of Approval
Retatrutide is under clinical development by Eli Lilly and Co and currently in Phase III for Type 2 Diabetes. According...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Retatrutide?
Retatrutide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase III program in Type 2...
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's Retatrutide?
Retatrutide is a synthetic peptide commercialized by Eli Lilly and Co, with a leading Phase III program in Obstructive Sleep...